SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution.

Current methods for studying cellular metabolism often rely on bulk analysis, which obscures heterogeneity among cell types. Prior research has shown that metabolic reprogramming is essential in cancer progression and immune responses. However, no prior work had resolved how individual cells within a mixed population respond metabolically. This gap motivated the development of techniques that can functionally profile metabolism at the single-cell level. Existing approaches lack the resolution to study rare cell subpopulations. Researchers have proposed that flow cytometry could be adapted for this purpose. But no method had combined metabolic profiling with single-cell resolution in a practical way. This uncertainty drove the need for a novel approach that could capture metabolic dependencies without culture bias.

The goal of this study was to develop a functional metabolic profiling method suitable for single-cell analysis. The authors aimed to overcome limitations of bulk assays by enabling ex vivo metabolic studies. They focused on rare cell types, such as those found in whole blood or tumor samples. The study sought to identify how different cell types respond metabolically without altering their environment. Researchers wanted to avoid biases introduced by in vitro culture conditions. They proposed that such a method could improve understanding of immune and cancer cell metabolism. The approach needed to be scalable and compatible with flow cytometry. The ultimate aim was to provide a tool for evaluating therapeutic responses and patient stratification.

The researchers developed SCENITH, a flow cytometry-based method for metabolic profiling. SCENITH uses translation inhibition to assess energy metabolism in single cells. The method is designed for ex vivo analysis, preserving natural metabolic states. It allows parallel study of multiple cell types within a sample. The approach avoids the use of culture media, which can alter metabolic profiles. SCENITH enables functional profiling of rare cell populations in whole blood. The method relies on detecting metabolic dependencies and capacities. It is optimized for use with solid tumor samples and immune cells.

SCENITH successfully identified variable metabolic profiles in myeloid cells from solid tumors. The method revealed distinct metabolic responses not linked to lineage or activation status. These findings suggest that metabolic heterogeneity exists within similar cell types. SCENITH's ability to detect complex immune-phenotypes was confirmed in rare cell subpopulations. The method provided global metabolic insights without culture bias. Results showed that metabolic profiles differ even among cells with similar phenotypes. SCENITH enabled functional analysis of cells in their native state. The approach demonstrated potential for clinical applications in patient stratification.

The authors propose that SCENITH offers a novel way to study metabolic responses in single cells. They suggest that the method can reveal metabolic dependencies not detectable in bulk assays. The findings indicate that metabolic heterogeneity exists within tumor-associated myeloid cells. SCENITH's ex vivo design preserves natural metabolic states. The method may help identify therapeutic targets in rare cell populations. The authors suggest that SCENITH could improve patient evaluation strategies. They propose that the approach supports more accurate metabolic profiling. The study concludes that SCENITH contributes to understanding immune and cancer metabolism.